nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—LPAR1—hematologic cancer	0.00103	0.0146	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL17—hematologic cancer	0.000977	0.0139	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR5—hematologic cancer	0.000959	0.0136	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCR7—hematologic cancer	0.000847	0.012	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL13—hematologic cancer	0.000847	0.012	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—TRH—hematologic cancer	0.000787	0.0112	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—LPAR1—hematologic cancer	0.000762	0.0108	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCL17—hematologic cancer	0.000744	0.0106	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCR5—hematologic cancer	0.00073	0.0104	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—RASGRP1—hematologic cancer	0.000723	0.0103	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—hematologic cancer	0.000702	0.00997	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RASGRP1—hematologic cancer	0.000646	0.00919	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCR7—hematologic cancer	0.000645	0.00917	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL13—hematologic cancer	0.000645	0.00917	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL3—hematologic cancer	0.000603	0.00858	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—TRH—hematologic cancer	0.0006	0.00852	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRB2—hematologic cancer	0.000581	0.00826	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—PTGER4—hematologic cancer	0.000581	0.00826	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—LPAR1—hematologic cancer	0.000581	0.00825	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CNR2—hematologic cancer	0.000534	0.0076	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCR4—hematologic cancer	0.000513	0.00729	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK1—hematologic cancer	0.000501	0.00712	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RHOJ—hematologic cancer	0.000491	0.00698	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—ARHGEF12—hematologic cancer	0.000481	0.00684	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—ARHGEF1—hematologic cancer	0.000469	0.00666	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCL3—hematologic cancer	0.000459	0.00653	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PTHLH—hematologic cancer	0.000454	0.00646	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—PTGER4—hematologic cancer	0.000442	0.00629	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IFT172—hematologic cancer	0.000438	0.00622	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—ARHGEF12—hematologic cancer	0.000437	0.00621	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—ARHGEF1—hematologic cancer	0.000426	0.00605	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCR5—hematologic cancer	0.000413	0.00586	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PPEF1—hematologic cancer	0.0004	0.00569	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GNA13—hematologic cancer	0.000398	0.00566	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—TIAM1—hematologic cancer	0.000392	0.00557	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCR4—hematologic cancer	0.000391	0.00555	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—hematologic cancer	0.000383	0.00545	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCL17—hematologic cancer	0.000382	0.00543	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—JAK3—hematologic cancer	0.00038	0.0054	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCR5—hematologic cancer	0.000375	0.00533	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CREB1—hematologic cancer	0.000371	0.00528	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL13—hematologic cancer	0.000364	0.00518	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CCR7—hematologic cancer	0.000364	0.00518	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—hematologic cancer	0.000362	0.00515	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—PIK3R1—hematologic cancer	0.000362	0.00514	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GNA13—hematologic cancer	0.000362	0.00514	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—TIAM1—hematologic cancer	0.000356	0.00506	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—IL3RA—hematologic cancer	0.000355	0.00505	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—JAK3—hematologic cancer	0.000345	0.00491	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—hematologic cancer	0.000345	0.0049	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RGS2—hematologic cancer	0.000343	0.00487	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—TRH—hematologic cancer	0.000339	0.00482	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—TRIO—hematologic cancer	0.000339	0.00482	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL13—hematologic cancer	0.000331	0.0047	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCR7—hematologic cancer	0.000331	0.0047	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—LPAR1—hematologic cancer	0.000328	0.00466	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3R1—hematologic cancer	0.000324	0.0046	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL3RA—hematologic cancer	0.000323	0.00458	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HDAC11—hematologic cancer	0.000316	0.0045	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—JAK2—hematologic cancer	0.000315	0.00447	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RGS2—hematologic cancer	0.000311	0.00442	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—TRH—hematologic cancer	0.000308	0.00437	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—TRIO—hematologic cancer	0.000308	0.00437	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BCR—hematologic cancer	0.000303	0.00431	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PDE4B—hematologic cancer	0.000302	0.00429	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CNR2—hematologic cancer	0.000302	0.00429	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—LPAR1—hematologic cancer	0.000298	0.00424	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RAC2—hematologic cancer	0.000297	0.00422	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—ADCY7—hematologic cancer	0.000284	0.00404	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HDAC10—hematologic cancer	0.000282	0.00401	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PDE4B—hematologic cancer	0.000274	0.0039	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CNR2—hematologic cancer	0.000274	0.0039	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RAC2—hematologic cancer	0.00027	0.00383	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCL2—hematologic cancer	0.000269	0.00382	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ARHGEF12—hematologic cancer	0.000258	0.00367	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—ADCY7—hematologic cancer	0.000258	0.00366	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PTHLH—hematologic cancer	0.000257	0.00365	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ARHGEF1—hematologic cancer	0.000251	0.00357	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PTGER4—hematologic cancer	0.00025	0.00355	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CCL3—hematologic cancer	0.000236	0.00335	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PTHLH—hematologic cancer	0.000233	0.00331	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—hematologic cancer	0.00023	0.00327	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PTGER4—hematologic cancer	0.000227	0.00323	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AGRN—hematologic cancer	0.000225	0.0032	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCL17—hematologic cancer	0.000225	0.0032	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCR5—hematologic cancer	0.000221	0.00315	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCR4—hematologic cancer	0.000221	0.00314	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—hematologic cancer	0.000221	0.00314	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LEF1—hematologic cancer	0.000217	0.00309	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GNA13—hematologic cancer	0.000214	0.00304	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—IL3—hematologic cancer	0.000213	0.00303	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TIAM1—hematologic cancer	0.00021	0.00299	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—RASGRP1—hematologic cancer	0.000206	0.00293	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CCL2—hematologic cancer	0.000205	0.00291	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JAK3—hematologic cancer	0.000204	0.0029	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—PIK3CA—hematologic cancer	0.000204	0.00289	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCR4—hematologic cancer	0.0002	0.00285	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—hematologic cancer	0.000198	0.00282	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCR7—hematologic cancer	0.000195	0.00278	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL13—hematologic cancer	0.000195	0.00278	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL3—hematologic cancer	0.000193	0.00275	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NCOR2—hematologic cancer	0.000193	0.00274	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL3RA—hematologic cancer	0.000191	0.00271	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CRKL—hematologic cancer	0.000191	0.00271	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RASGRP1—hematologic cancer	0.000187	0.00266	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GRB2—hematologic cancer	0.000185	0.00263	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RGS2—hematologic cancer	0.000184	0.00261	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—hematologic cancer	0.000182	0.00259	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TRIO—hematologic cancer	0.000182	0.00258	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TRH—hematologic cancer	0.000182	0.00258	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CMA1—hematologic cancer	0.000182	0.00258	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AGO2—hematologic cancer	0.000178	0.00253	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SPHK1—hematologic cancer	0.000178	0.00253	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HDAC9—hematologic cancer	0.000176	0.0025	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—LPAR1—hematologic cancer	0.000176	0.0025	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—H3F3B—hematologic cancer	0.000174	0.00248	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—hematologic cancer	0.000169	0.0024	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GRB2—hematologic cancer	0.000168	0.00239	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CSF2—hematologic cancer	0.000165	0.00235	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDE4B—hematologic cancer	0.000162	0.0023	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CNR2—hematologic cancer	0.000162	0.0023	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hematologic cancer	0.000161	0.00229	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FGF19—hematologic cancer	0.000161	0.00228	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PRKCG—hematologic cancer	0.00016	0.00227	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—JAK1—hematologic cancer	0.00016	0.00227	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RAC2—hematologic cancer	0.000159	0.00227	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—DKK1—hematologic cancer	0.000158	0.00225	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT5B—hematologic cancer	0.000157	0.00223	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ADCY7—hematologic cancer	0.000152	0.00216	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CSF2—hematologic cancer	0.00015	0.00214	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—IL2RA—hematologic cancer	0.000149	0.00212	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—XIAP—hematologic cancer	0.000148	0.00211	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PRKCG—hematologic cancer	0.000145	0.00206	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—JAK1—hematologic cancer	0.000145	0.00206	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SMARCA4—hematologic cancer	0.000144	0.00205	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SH2B3—hematologic cancer	0.000144	0.00205	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GZMB—hematologic cancer	0.000143	0.00204	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CTNNA1—hematologic cancer	0.00014	0.00199	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EIF4EBP1—hematologic cancer	0.000139	0.00198	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCL3—hematologic cancer	0.000139	0.00198	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HSPB1—hematologic cancer	0.000139	0.00198	CbGpPWpGaD
Degarelix—Feeling abnormal—Triamcinolone—hematologic cancer	0.000139	0.000149	CcSEcCtD
Degarelix—Diarrhoea—Cisplatin—hematologic cancer	0.000139	0.000149	CcSEcCtD
Degarelix—Alopecia—Methotrexate—hematologic cancer	0.000138	0.000149	CcSEcCtD
Degarelix—Vomiting—Gemcitabine—hematologic cancer	0.000138	0.000149	CcSEcCtD
Degarelix—Insomnia—Dexamethasone—hematologic cancer	0.000138	0.000148	CcSEcCtD
Degarelix—Insomnia—Betamethasone—hematologic cancer	0.000138	0.000148	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PTHLH—hematologic cancer	0.000138	0.00196	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SDC1—hematologic cancer	0.000138	0.00196	CbGpPWpGaD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	0.000138	0.000148	CcSEcCtD
Degarelix—Discomfort—Prednisone—hematologic cancer	0.000137	0.000147	CcSEcCtD
Degarelix—Mental disorder—Methotrexate—hematologic cancer	0.000137	0.000147	CcSEcCtD
Degarelix—Rash—Gemcitabine—hematologic cancer	0.000137	0.000147	CcSEcCtD
Degarelix—Dermatitis—Gemcitabine—hematologic cancer	0.000137	0.000147	CcSEcCtD
Degarelix—Eye disorder—Epirubicin—hematologic cancer	0.000137	0.000147	CcSEcCtD
Degarelix—Hypersensitivity—Etoposide—hematologic cancer	0.000137	0.000147	CcSEcCtD
Degarelix—Erythema—Methotrexate—hematologic cancer	0.000136	0.000146	CcSEcCtD
Degarelix—Malnutrition—Methotrexate—hematologic cancer	0.000136	0.000146	CcSEcCtD
Degarelix—Headache—Gemcitabine—hematologic cancer	0.000136	0.000146	CcSEcCtD
Degarelix—Nausea—Vincristine—hematologic cancer	0.000136	0.000146	CcSEcCtD
Degarelix—Cardiac disorder—Epirubicin—hematologic cancer	0.000136	0.000146	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—IL2RA—hematologic cancer	0.000135	0.00193	CbGpPWpGaD
Degarelix—Hypersensitivity—Prednisolone—hematologic cancer	0.000135	0.000145	CcSEcCtD
Degarelix—Hypoaesthesia—Doxorubicin—hematologic cancer	0.000135	0.000145	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PTGER4—hematologic cancer	0.000134	0.00191	CbGpPWpGaD
Degarelix—Urinary tract disorder—Doxorubicin—hematologic cancer	0.000134	0.000144	CcSEcCtD
Degarelix—Urticaria—Triamcinolone—hematologic cancer	0.000134	0.000144	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—LCK—hematologic cancer	0.000133	0.0019	CbGpPWpGaD
Degarelix—Oedema peripheral—Doxorubicin—hematologic cancer	0.000133	0.000143	CcSEcCtD
Degarelix—Asthenia—Etoposide—hematologic cancer	0.000133	0.000143	CcSEcCtD
Degarelix—Body temperature increased—Triamcinolone—hematologic cancer	0.000133	0.000143	CcSEcCtD
Degarelix—Anaphylactic shock—Prednisone—hematologic cancer	0.000133	0.000143	CcSEcCtD
Degarelix—Angiopathy—Epirubicin—hematologic cancer	0.000133	0.000143	CcSEcCtD
Degarelix—Urethral disorder—Doxorubicin—hematologic cancer	0.000133	0.000143	CcSEcCtD
Degarelix—Decreased appetite—Dexamethasone—hematologic cancer	0.000133	0.000143	CcSEcCtD
Degarelix—Decreased appetite—Betamethasone—hematologic cancer	0.000133	0.000143	CcSEcCtD
Degarelix—Nausea—Mitoxantrone—hematologic cancer	0.000132	0.000142	CcSEcCtD
Degarelix—Nausea—Irinotecan—hematologic cancer	0.000132	0.000142	CcSEcCtD
Degarelix—Immune system disorder—Epirubicin—hematologic cancer	0.000132	0.000142	CcSEcCtD
Degarelix—Mediastinal disorder—Epirubicin—hematologic cancer	0.000132	0.000142	CcSEcCtD
Degarelix—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000132	0.000142	CcSEcCtD
Degarelix—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000132	0.000142	CcSEcCtD
Degarelix—Back pain—Methotrexate—hematologic cancer	0.000132	0.000142	CcSEcCtD
Degarelix—Fatigue—Dexamethasone—hematologic cancer	0.000132	0.000142	CcSEcCtD
Degarelix—Fatigue—Betamethasone—hematologic cancer	0.000132	0.000142	CcSEcCtD
Degarelix—Chills—Epirubicin—hematologic cancer	0.000131	0.000141	CcSEcCtD
Degarelix—Pruritus—Etoposide—hematologic cancer	0.000131	0.000141	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—H3F3A—hematologic cancer	0.000131	0.00186	CbGpPWpGaD
Degarelix—Arrhythmia—Epirubicin—hematologic cancer	0.000131	0.000141	CcSEcCtD
Degarelix—Pain—Dexamethasone—hematologic cancer	0.000131	0.00014	CcSEcCtD
Degarelix—Pain—Betamethasone—hematologic cancer	0.000131	0.00014	CcSEcCtD
Degarelix—Nervous system disorder—Prednisone—hematologic cancer	0.00013	0.00014	CcSEcCtD
Degarelix—Alopecia—Epirubicin—hematologic cancer	0.000129	0.000139	CcSEcCtD
Degarelix—Skin disorder—Prednisone—hematologic cancer	0.000129	0.000139	CcSEcCtD
Degarelix—Nausea—Gemcitabine—hematologic cancer	0.000129	0.000139	CcSEcCtD
Degarelix—Vomiting—Cisplatin—hematologic cancer	0.000129	0.000138	CcSEcCtD
Degarelix—Hyperhidrosis—Prednisone—hematologic cancer	0.000128	0.000138	CcSEcCtD
Degarelix—Vision blurred—Methotrexate—hematologic cancer	0.000128	0.000138	CcSEcCtD
Degarelix—Mental disorder—Epirubicin—hematologic cancer	0.000128	0.000138	CcSEcCtD
Degarelix—Rash—Cisplatin—hematologic cancer	0.000128	0.000137	CcSEcCtD
Degarelix—Dermatitis—Cisplatin—hematologic cancer	0.000128	0.000137	CcSEcCtD
Degarelix—Malnutrition—Epirubicin—hematologic cancer	0.000127	0.000137	CcSEcCtD
Degarelix—Erythema—Epirubicin—hematologic cancer	0.000127	0.000137	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PRKCZ—hematologic cancer	0.000127	0.00181	CbGpPWpGaD
Degarelix—Diarrhoea—Etoposide—hematologic cancer	0.000127	0.000136	CcSEcCtD
Degarelix—Eye disorder—Doxorubicin—hematologic cancer	0.000127	0.000136	CcSEcCtD
Degarelix—Ill-defined disorder—Methotrexate—hematologic cancer	0.000126	0.000136	CcSEcCtD
Degarelix—Anaemia—Methotrexate—hematologic cancer	0.000126	0.000135	CcSEcCtD
Degarelix—Feeling abnormal—Dexamethasone—hematologic cancer	0.000126	0.000135	CcSEcCtD
Degarelix—Feeling abnormal—Betamethasone—hematologic cancer	0.000126	0.000135	CcSEcCtD
Degarelix—Cardiac disorder—Doxorubicin—hematologic cancer	0.000126	0.000135	CcSEcCtD
Degarelix—Gastrointestinal pain—Betamethasone—hematologic cancer	0.000125	0.000134	CcSEcCtD
Degarelix—Gastrointestinal pain—Dexamethasone—hematologic cancer	0.000125	0.000134	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CG—hematologic cancer	0.000124	0.00177	CbGpPWpGaD
Degarelix—Hypersensitivity—Triamcinolone—hematologic cancer	0.000124	0.000133	CcSEcCtD
Degarelix—Back pain—Epirubicin—hematologic cancer	0.000123	0.000133	CcSEcCtD
Degarelix—Angiopathy—Doxorubicin—hematologic cancer	0.000123	0.000132	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PARP1—hematologic cancer	0.000123	0.00175	CbGpPWpGaD
Degarelix—Malaise—Methotrexate—hematologic cancer	0.000123	0.000132	CcSEcCtD
Degarelix—Dizziness—Etoposide—hematologic cancer	0.000123	0.000132	CcSEcCtD
Degarelix—Muscle spasms—Epirubicin—hematologic cancer	0.000122	0.000132	CcSEcCtD
Degarelix—Immune system disorder—Doxorubicin—hematologic cancer	0.000122	0.000132	CcSEcCtD
Degarelix—Mediastinal disorder—Doxorubicin—hematologic cancer	0.000122	0.000131	CcSEcCtD
Degarelix—Chills—Doxorubicin—hematologic cancer	0.000121	0.000131	CcSEcCtD
Degarelix—Urticaria—Betamethasone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—Urticaria—Dexamethasone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Prednisone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—Dizziness—Prednisolone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—Arrhythmia—Doxorubicin—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FBXW7—hematologic cancer	0.000121	0.00172	CbGpPWpGaD
Degarelix—Asthenia—Triamcinolone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—Body temperature increased—Dexamethasone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—Body temperature increased—Betamethasone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—Abdominal pain—Dexamethasone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—Abdominal pain—Betamethasone—hematologic cancer	0.000121	0.00013	CcSEcCtD
Degarelix—Nausea—Cisplatin—hematologic cancer	0.00012	0.000129	CcSEcCtD
Degarelix—Insomnia—Prednisone—hematologic cancer	0.00012	0.000129	CcSEcCtD
Degarelix—Vision blurred—Epirubicin—hematologic cancer	0.00012	0.000129	CcSEcCtD
Degarelix—Alopecia—Doxorubicin—hematologic cancer	0.00012	0.000129	CcSEcCtD
Degarelix—Pruritus—Triamcinolone—hematologic cancer	0.000119	0.000128	CcSEcCtD
Degarelix—Mental disorder—Doxorubicin—hematologic cancer	0.000119	0.000128	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CXCR4—hematologic cancer	0.000118	0.00168	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HDAC2—hematologic cancer	0.000118	0.00168	CbGpPWpGaD
Degarelix—Ill-defined disorder—Epirubicin—hematologic cancer	0.000118	0.000127	CcSEcCtD
Degarelix—Vomiting—Etoposide—hematologic cancer	0.000118	0.000127	CcSEcCtD
Degarelix—Erythema—Doxorubicin—hematologic cancer	0.000118	0.000127	CcSEcCtD
Degarelix—Malnutrition—Doxorubicin—hematologic cancer	0.000118	0.000127	CcSEcCtD
Degarelix—Anaemia—Epirubicin—hematologic cancer	0.000118	0.000127	CcSEcCtD
Degarelix—Rash—Etoposide—hematologic cancer	0.000117	0.000126	CcSEcCtD
Degarelix—Dermatitis—Etoposide—hematologic cancer	0.000117	0.000126	CcSEcCtD
Degarelix—Headache—Etoposide—hematologic cancer	0.000116	0.000125	CcSEcCtD
Degarelix—Arthralgia—Methotrexate—hematologic cancer	0.000116	0.000125	CcSEcCtD
Degarelix—Decreased appetite—Prednisone—hematologic cancer	0.000116	0.000124	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CBL—hematologic cancer	0.000115	0.00164	CbGpPWpGaD
Degarelix—Rash—Prednisolone—hematologic cancer	0.000115	0.000124	CcSEcCtD
Degarelix—Dermatitis—Prednisolone—hematologic cancer	0.000115	0.000124	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	0.000115	0.000124	CcSEcCtD
Degarelix—Malaise—Epirubicin—hematologic cancer	0.000115	0.000124	CcSEcCtD
Degarelix—Fatigue—Prednisone—hematologic cancer	0.000115	0.000123	CcSEcCtD
Degarelix—Headache—Prednisolone—hematologic cancer	0.000115	0.000123	CcSEcCtD
Degarelix—Discomfort—Methotrexate—hematologic cancer	0.000114	0.000123	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—IL3—hematologic cancer	0.000114	0.00162	CbGpPWpGaD
Degarelix—Back pain—Doxorubicin—hematologic cancer	0.000114	0.000123	CcSEcCtD
Degarelix—Constipation—Prednisone—hematologic cancer	0.000114	0.000122	CcSEcCtD
Degarelix—Muscle spasms—Doxorubicin—hematologic cancer	0.000113	0.000122	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PIK3CG—hematologic cancer	0.000113	0.0016	CbGpPWpGaD
Degarelix—Palpitations—Epirubicin—hematologic cancer	0.000113	0.000121	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PTPN1—hematologic cancer	0.000112	0.0016	CbGpPWpGaD
Degarelix—Dizziness—Triamcinolone—hematologic cancer	0.000111	0.00012	CcSEcCtD
Degarelix—Anaphylactic shock—Methotrexate—hematologic cancer	0.000111	0.000119	CcSEcCtD
Degarelix—Vision blurred—Doxorubicin—hematologic cancer	0.000111	0.000119	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PTPN11—hematologic cancer	0.000111	0.00158	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RASGRP1—hematologic cancer	0.00011	0.00157	CbGpPWpGaD
Degarelix—Nausea—Etoposide—hematologic cancer	0.00011	0.000118	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—SYK—hematologic cancer	0.00011	0.00157	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HSP90AA1—hematologic cancer	0.00011	0.00157	CbGpPWpGaD
Degarelix—Hypertension—Epirubicin—hematologic cancer	0.00011	0.000118	CcSEcCtD
Degarelix—Feeling abnormal—Prednisone—hematologic cancer	0.00011	0.000118	CcSEcCtD
Degarelix—Asthenia—Dexamethasone—hematologic cancer	0.00011	0.000118	CcSEcCtD
Degarelix—Asthenia—Betamethasone—hematologic cancer	0.00011	0.000118	CcSEcCtD
Degarelix—Ill-defined disorder—Doxorubicin—hematologic cancer	0.000109	0.000118	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CD—hematologic cancer	0.000109	0.00155	CbGpPWpGaD
Degarelix—Nervous system disorder—Methotrexate—hematologic cancer	0.000109	0.000117	CcSEcCtD
Degarelix—Anaemia—Doxorubicin—hematologic cancer	0.000109	0.000117	CcSEcCtD
Degarelix—Gastrointestinal pain—Prednisone—hematologic cancer	0.000109	0.000117	CcSEcCtD
Degarelix—Nausea—Prednisolone—hematologic cancer	0.000109	0.000117	CcSEcCtD
Degarelix—Arthralgia—Epirubicin—hematologic cancer	0.000108	0.000117	CcSEcCtD
Degarelix—Pruritus—Betamethasone—hematologic cancer	0.000108	0.000116	CcSEcCtD
Degarelix—Pruritus—Dexamethasone—hematologic cancer	0.000108	0.000116	CcSEcCtD
Degarelix—Skin disorder—Methotrexate—hematologic cancer	0.000108	0.000116	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	0.000108	0.000116	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CREB1—hematologic cancer	0.000107	0.00153	CbGpPWpGaD
Degarelix—Hyperhidrosis—Methotrexate—hematologic cancer	0.000107	0.000116	CcSEcCtD
Degarelix—Discomfort—Epirubicin—hematologic cancer	0.000107	0.000115	CcSEcCtD
Degarelix—Vomiting—Triamcinolone—hematologic cancer	0.000107	0.000115	CcSEcCtD
Degarelix—Malaise—Doxorubicin—hematologic cancer	0.000106	0.000114	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—STAT1—hematologic cancer	0.000106	0.00151	CbGpPWpGaD
Degarelix—Rash—Triamcinolone—hematologic cancer	0.000106	0.000114	CcSEcCtD
Degarelix—Dry mouth—Epirubicin—hematologic cancer	0.000106	0.000114	CcSEcCtD
Degarelix—Dermatitis—Triamcinolone—hematologic cancer	0.000106	0.000114	CcSEcCtD
Degarelix—Urticaria—Prednisone—hematologic cancer	0.000106	0.000114	CcSEcCtD
Degarelix—Headache—Triamcinolone—hematologic cancer	0.000105	0.000113	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—CCL2—hematologic cancer	0.000105	0.00149	CbGpPWpGaD
Degarelix—Abdominal pain—Prednisone—hematologic cancer	0.000105	0.000113	CcSEcCtD
Degarelix—Body temperature increased—Prednisone—hematologic cancer	0.000105	0.000113	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—IL6R—hematologic cancer	0.000105	0.00149	CbGpPWpGaD
Degarelix—Diarrhoea—Dexamethasone—hematologic cancer	0.000104	0.000112	CcSEcCtD
Degarelix—Diarrhoea—Betamethasone—hematologic cancer	0.000104	0.000112	CcSEcCtD
Degarelix—Palpitations—Doxorubicin—hematologic cancer	0.000104	0.000112	CcSEcCtD
Degarelix—Anaphylactic shock—Epirubicin—hematologic cancer	0.000104	0.000112	CcSEcCtD
Degarelix—Hypotension—Methotrexate—hematologic cancer	0.000104	0.000112	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3R1—hematologic cancer	0.000103	0.00147	CbGpPWpGaD
Degarelix—Nervous system disorder—Epirubicin—hematologic cancer	0.000102	0.00011	CcSEcCtD
Degarelix—Hypertension—Doxorubicin—hematologic cancer	0.000102	0.000109	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Methotrexate—hematologic cancer	0.000101	0.000109	CcSEcCtD
Degarelix—Skin disorder—Epirubicin—hematologic cancer	0.000101	0.000109	CcSEcCtD
Degarelix—Dizziness—Betamethasone—hematologic cancer	0.000101	0.000109	CcSEcCtD
Degarelix—Dizziness—Dexamethasone—hematologic cancer	0.000101	0.000109	CcSEcCtD
Degarelix—Hyperhidrosis—Epirubicin—hematologic cancer	0.0001	0.000108	CcSEcCtD
Degarelix—Insomnia—Methotrexate—hematologic cancer	0.0001	0.000108	CcSEcCtD
Degarelix—Arthralgia—Doxorubicin—hematologic cancer	0.0001	0.000108	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—JAK2—hematologic cancer	0.0001	0.00142	CbGpPWpGaD
Degarelix—Nausea—Triamcinolone—hematologic cancer	9.99e-05	0.000107	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—MAP2K1—hematologic cancer	9.98e-05	0.00142	CbGpPWpGaD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	9.96e-05	0.000107	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GRB2—hematologic cancer	9.93e-05	0.00141	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CD—hematologic cancer	9.92e-05	0.00141	CbGpPWpGaD
Degarelix—Discomfort—Doxorubicin—hematologic cancer	9.91e-05	0.000107	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PDGFA—hematologic cancer	9.91e-05	0.00141	CbGpPWpGaD
Degarelix—Dyspnoea—Methotrexate—hematologic cancer	9.9e-05	0.000107	CcSEcCtD
Degarelix—Dry mouth—Doxorubicin—hematologic cancer	9.81e-05	0.000106	CcSEcCtD
Degarelix—Hypersensitivity—Prednisone—hematologic cancer	9.79e-05	0.000105	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—KITLG—hematologic cancer	9.77e-05	0.00139	CbGpPWpGaD
Degarelix—Hypotension—Epirubicin—hematologic cancer	9.71e-05	0.000104	CcSEcCtD
Degarelix—Vomiting—Betamethasone—hematologic cancer	9.7e-05	0.000104	CcSEcCtD
Degarelix—Vomiting—Dexamethasone—hematologic cancer	9.7e-05	0.000104	CcSEcCtD
Degarelix—Decreased appetite—Methotrexate—hematologic cancer	9.66e-05	0.000104	CcSEcCtD
Degarelix—Rash—Dexamethasone—hematologic cancer	9.62e-05	0.000104	CcSEcCtD
Degarelix—Rash—Betamethasone—hematologic cancer	9.62e-05	0.000104	CcSEcCtD
Degarelix—Anaphylactic shock—Doxorubicin—hematologic cancer	9.62e-05	0.000103	CcSEcCtD
Degarelix—Dermatitis—Betamethasone—hematologic cancer	9.61e-05	0.000103	CcSEcCtD
Degarelix—Dermatitis—Dexamethasone—hematologic cancer	9.61e-05	0.000103	CcSEcCtD
Degarelix—Gastrointestinal disorder—Methotrexate—hematologic cancer	9.59e-05	0.000103	CcSEcCtD
Degarelix—Fatigue—Methotrexate—hematologic cancer	9.58e-05	0.000103	CcSEcCtD
Degarelix—Headache—Dexamethasone—hematologic cancer	9.56e-05	0.000103	CcSEcCtD
Degarelix—Headache—Betamethasone—hematologic cancer	9.56e-05	0.000103	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—STAT5A—hematologic cancer	9.55e-05	0.00136	CbGpPWpGaD
Degarelix—Asthenia—Prednisone—hematologic cancer	9.54e-05	0.000103	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CB—hematologic cancer	9.52e-05	0.00135	CbGpPWpGaD
Degarelix—Pain—Methotrexate—hematologic cancer	9.5e-05	0.000102	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.47e-05	0.000102	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CDKN2B—hematologic cancer	9.46e-05	0.00135	CbGpPWpGaD
Degarelix—Nervous system disorder—Doxorubicin—hematologic cancer	9.43e-05	0.000101	CcSEcCtD
Degarelix—Pruritus—Prednisone—hematologic cancer	9.4e-05	0.000101	CcSEcCtD
Degarelix—Insomnia—Epirubicin—hematologic cancer	9.4e-05	0.000101	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PIK3R1—hematologic cancer	9.37e-05	0.00133	CbGpPWpGaD
Degarelix—Skin disorder—Doxorubicin—hematologic cancer	9.34e-05	0.0001	CcSEcCtD
Degarelix—Hyperhidrosis—Doxorubicin—hematologic cancer	9.3e-05	0.0001	CcSEcCtD
Degarelix—Dyspnoea—Epirubicin—hematologic cancer	9.27e-05	9.97e-05	CcSEcCtD
Degarelix—Feeling abnormal—Methotrexate—hematologic cancer	9.15e-05	9.85e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CD86—hematologic cancer	9.15e-05	0.0013	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—JAK2—hematologic cancer	9.1e-05	0.00129	CbGpPWpGaD
Degarelix—Diarrhoea—Prednisone—hematologic cancer	9.09e-05	9.78e-05	CcSEcCtD
Degarelix—Gastrointestinal pain—Methotrexate—hematologic cancer	9.08e-05	9.77e-05	CcSEcCtD
Degarelix—Nausea—Dexamethasone—hematologic cancer	9.07e-05	9.75e-05	CcSEcCtD
Degarelix—Nausea—Betamethasone—hematologic cancer	9.07e-05	9.75e-05	CcSEcCtD
Degarelix—Decreased appetite—Epirubicin—hematologic cancer	9.04e-05	9.72e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—HES1—hematologic cancer	9.03e-05	0.00128	CbGpPWpGaD
Degarelix—Hypotension—Doxorubicin—hematologic cancer	8.99e-05	9.67e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NCOR1—hematologic cancer	8.98e-05	0.00128	CbGpPWpGaD
Degarelix—Gastrointestinal disorder—Epirubicin—hematologic cancer	8.97e-05	9.65e-05	CcSEcCtD
Degarelix—Fatigue—Epirubicin—hematologic cancer	8.96e-05	9.64e-05	CcSEcCtD
Degarelix—Constipation—Epirubicin—hematologic cancer	8.89e-05	9.56e-05	CcSEcCtD
Degarelix—Pain—Epirubicin—hematologic cancer	8.89e-05	9.56e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGF1—hematologic cancer	8.88e-05	0.00126	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CSF2—hematologic cancer	8.88e-05	0.00126	CbGpPWpGaD
Degarelix—Urticaria—Methotrexate—hematologic cancer	8.82e-05	9.49e-05	CcSEcCtD
Degarelix—Dizziness—Prednisone—hematologic cancer	8.79e-05	9.45e-05	CcSEcCtD
Degarelix—Abdominal pain—Methotrexate—hematologic cancer	8.78e-05	9.45e-05	CcSEcCtD
Degarelix—Body temperature increased—Methotrexate—hematologic cancer	8.78e-05	9.45e-05	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	8.76e-05	9.43e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FOXO1—hematologic cancer	8.75e-05	0.00124	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—IL2—hematologic cancer	8.74e-05	0.00124	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDGFRB—hematologic cancer	8.73e-05	0.00124	CbGpPWpGaD
Degarelix—Insomnia—Doxorubicin—hematologic cancer	8.7e-05	9.36e-05	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PIK3CB—hematologic cancer	8.65e-05	0.00123	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PDGFRA—hematologic cancer	8.6e-05	0.00122	CbGpPWpGaD
Degarelix—Dyspnoea—Doxorubicin—hematologic cancer	8.58e-05	9.22e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—JAK1—hematologic cancer	8.57e-05	0.00122	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PRKCG—hematologic cancer	8.57e-05	0.00122	CbGpPWpGaD
Degarelix—Feeling abnormal—Epirubicin—hematologic cancer	8.57e-05	9.21e-05	CcSEcCtD
Degarelix—Gastrointestinal pain—Epirubicin—hematologic cancer	8.5e-05	9.14e-05	CcSEcCtD
Degarelix—Vomiting—Prednisone—hematologic cancer	8.45e-05	9.09e-05	CcSEcCtD
Degarelix—Rash—Prednisone—hematologic cancer	8.38e-05	9.01e-05	CcSEcCtD
Degarelix—Dermatitis—Prednisone—hematologic cancer	8.37e-05	9.01e-05	CcSEcCtD
Degarelix—Decreased appetite—Doxorubicin—hematologic cancer	8.36e-05	8.99e-05	CcSEcCtD
Degarelix—Headache—Prednisone—hematologic cancer	8.33e-05	8.96e-05	CcSEcCtD
Degarelix—Gastrointestinal disorder—Doxorubicin—hematologic cancer	8.3e-05	8.93e-05	CcSEcCtD
Degarelix—Fatigue—Doxorubicin—hematologic cancer	8.29e-05	8.92e-05	CcSEcCtD
Degarelix—Urticaria—Epirubicin—hematologic cancer	8.26e-05	8.88e-05	CcSEcCtD
Degarelix—Pain—Doxorubicin—hematologic cancer	8.23e-05	8.85e-05	CcSEcCtD
Degarelix—Constipation—Doxorubicin—hematologic cancer	8.23e-05	8.85e-05	CcSEcCtD
Degarelix—Body temperature increased—Epirubicin—hematologic cancer	8.22e-05	8.84e-05	CcSEcCtD
Degarelix—Abdominal pain—Epirubicin—hematologic cancer	8.22e-05	8.84e-05	CcSEcCtD
Degarelix—Hypersensitivity—Methotrexate—hematologic cancer	8.18e-05	8.8e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—IL2RA—hematologic cancer	8e-05	0.00114	CbGpPWpGaD
Degarelix—Asthenia—Methotrexate—hematologic cancer	7.97e-05	8.57e-05	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—IL2—hematologic cancer	7.94e-05	0.00113	CbGpPWpGaD
Degarelix—Feeling abnormal—Doxorubicin—hematologic cancer	7.93e-05	8.53e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TERT—hematologic cancer	7.91e-05	0.00112	CbGpPWpGaD
Degarelix—Nausea—Prednisone—hematologic cancer	7.89e-05	8.49e-05	CcSEcCtD
Degarelix—Gastrointestinal pain—Doxorubicin—hematologic cancer	7.87e-05	8.46e-05	CcSEcCtD
Degarelix—Pruritus—Methotrexate—hematologic cancer	7.86e-05	8.45e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PDGFB—hematologic cancer	7.72e-05	0.0011	CbGpPWpGaD
Degarelix—Hypersensitivity—Epirubicin—hematologic cancer	7.66e-05	8.24e-05	CcSEcCtD
Degarelix—Urticaria—Doxorubicin—hematologic cancer	7.64e-05	8.22e-05	CcSEcCtD
Degarelix—Body temperature increased—Doxorubicin—hematologic cancer	7.6e-05	8.18e-05	CcSEcCtD
Degarelix—Abdominal pain—Doxorubicin—hematologic cancer	7.6e-05	8.18e-05	CcSEcCtD
Degarelix—Diarrhoea—Methotrexate—hematologic cancer	7.6e-05	8.18e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—TSC2—hematologic cancer	7.55e-05	0.00107	CbGpPWpGaD
Degarelix—Asthenia—Epirubicin—hematologic cancer	7.46e-05	8.02e-05	CcSEcCtD
Degarelix—Pruritus—Epirubicin—hematologic cancer	7.35e-05	7.91e-05	CcSEcCtD
Degarelix—Dizziness—Methotrexate—hematologic cancer	7.35e-05	7.9e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGFR3—hematologic cancer	7.26e-05	0.00103	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK14—hematologic cancer	7.19e-05	0.00102	CbGpPWpGaD
Degarelix—Diarrhoea—Epirubicin—hematologic cancer	7.11e-05	7.65e-05	CcSEcCtD
Degarelix—Hypersensitivity—Doxorubicin—hematologic cancer	7.09e-05	7.62e-05	CcSEcCtD
Degarelix—Vomiting—Methotrexate—hematologic cancer	7.06e-05	7.6e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—ESR1—hematologic cancer	7.05e-05	0.001	CbGpPWpGaD
Degarelix—Rash—Methotrexate—hematologic cancer	7e-05	7.53e-05	CcSEcCtD
Degarelix—Dermatitis—Methotrexate—hematologic cancer	7e-05	7.53e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FN1—hematologic cancer	6.96e-05	0.00099	CbGpPWpGaD
Degarelix—Headache—Methotrexate—hematologic cancer	6.96e-05	7.49e-05	CcSEcCtD
Degarelix—Asthenia—Doxorubicin—hematologic cancer	6.9e-05	7.42e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NFKBIA—hematologic cancer	6.88e-05	0.000978	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BAD—hematologic cancer	6.88e-05	0.000978	CbGpPWpGaD
Degarelix—Dizziness—Epirubicin—hematologic cancer	6.87e-05	7.39e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—NOTCH1—hematologic cancer	6.82e-05	0.000969	CbGpPWpGaD
Degarelix—Pruritus—Doxorubicin—hematologic cancer	6.81e-05	7.32e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CD80—hematologic cancer	6.68e-05	0.000949	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CG—hematologic cancer	6.67e-05	0.000947	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KIT—hematologic cancer	6.67e-05	0.000947	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—NRAS—hematologic cancer	6.67e-05	0.000947	CbGpPWpGaD
Degarelix—Vomiting—Epirubicin—hematologic cancer	6.61e-05	7.11e-05	CcSEcCtD
Degarelix—Nausea—Methotrexate—hematologic cancer	6.6e-05	7.1e-05	CcSEcCtD
Degarelix—Diarrhoea—Doxorubicin—hematologic cancer	6.58e-05	7.08e-05	CcSEcCtD
Degarelix—Rash—Epirubicin—hematologic cancer	6.55e-05	7.05e-05	CcSEcCtD
Degarelix—Dermatitis—Epirubicin—hematologic cancer	6.55e-05	7.04e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—PTPN11—hematologic cancer	6.55e-05	0.000931	CbGpPWpGaD
Degarelix—Headache—Epirubicin—hematologic cancer	6.51e-05	7.01e-05	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—MAPK3—hematologic cancer	6.38e-05	0.000907	CbGpPWpGaD
Degarelix—Dizziness—Doxorubicin—hematologic cancer	6.36e-05	6.84e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—CREB1—hematologic cancer	6.34e-05	0.000902	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BRAF—hematologic cancer	6.27e-05	0.000891	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCL2—hematologic cancer	6.21e-05	0.000882	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6R—hematologic cancer	6.19e-05	0.00088	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CREBBP—hematologic cancer	6.18e-05	0.000878	CbGpPWpGaD
Degarelix—Nausea—Epirubicin—hematologic cancer	6.17e-05	6.64e-05	CcSEcCtD
Degarelix—Vomiting—Doxorubicin—hematologic cancer	6.12e-05	6.58e-05	CcSEcCtD
Degarelix—Rash—Doxorubicin—hematologic cancer	6.06e-05	6.52e-05	CcSEcCtD
Degarelix—Dermatitis—Doxorubicin—hematologic cancer	6.06e-05	6.52e-05	CcSEcCtD
Degarelix—Headache—Doxorubicin—hematologic cancer	6.03e-05	6.48e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—MAP2K1—hematologic cancer	5.9e-05	0.000838	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CD—hematologic cancer	5.86e-05	0.000833	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CA—hematologic cancer	5.8e-05	0.000825	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KRAS—hematologic cancer	5.74e-05	0.000815	CbGpPWpGaD
Degarelix—Nausea—Doxorubicin—hematologic cancer	5.71e-05	6.15e-05	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—FGF2—hematologic cancer	5.61e-05	0.000797	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3R1—hematologic cancer	5.53e-05	0.000786	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JAK2—hematologic cancer	5.38e-05	0.000764	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CA—hematologic cancer	5.27e-05	0.000749	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MDM2—hematologic cancer	5.25e-05	0.000746	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CB—hematologic cancer	5.11e-05	0.000726	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MTOR—hematologic cancer	5.11e-05	0.000726	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—HRAS—hematologic cancer	4.88e-05	0.000693	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1B—hematologic cancer	4.79e-05	0.000681	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AKT1—hematologic cancer	4.74e-05	0.000674	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CASP3—hematologic cancer	4.7e-05	0.000668	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL2—hematologic cancer	4.69e-05	0.000667	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6—hematologic cancer	4.67e-05	0.000663	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCND1—hematologic cancer	4.57e-05	0.00065	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JUN—hematologic cancer	4.56e-05	0.000649	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1A—hematologic cancer	4.42e-05	0.000629	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTEN—hematologic cancer	4.41e-05	0.000627	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK8—hematologic cancer	4.32e-05	0.000614	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AKT1—hematologic cancer	4.31e-05	0.000612	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EP300—hematologic cancer	4.21e-05	0.000598	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SRC—hematologic cancer	4.09e-05	0.000582	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFA—hematologic cancer	3.99e-05	0.000567	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT3—hematologic cancer	3.95e-05	0.000561	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NRAS—hematologic cancer	3.94e-05	0.00056	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK3—hematologic cancer	3.77e-05	0.000536	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MYC—hematologic cancer	3.67e-05	0.000521	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TGFB1—hematologic cancer	3.66e-05	0.00052	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KRAS—hematologic cancer	3.39e-05	0.000482	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CA—hematologic cancer	3.11e-05	0.000443	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TP53—hematologic cancer	3.01e-05	0.000428	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HRAS—hematologic cancer	2.88e-05	0.000409	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6—hematologic cancer	2.76e-05	0.000392	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT1—hematologic cancer	2.54e-05	0.000362	CbGpPWpGaD
